The researchers found that patients receiving Cypher were at much lower risk of having their arteries reclose than those who received Taxus.

FORBES: Studies Give Edge To J&J Stent

The company is already conducting a big U.S. clinical trial that will compare its stent to Boston Scientific's on actual clinical endpoints such as heart attacks and deaths, rather than just whether it causes arteries to reclose.

FORBES: J&J Targets Stent Maker